| Objective:Observe the clinical efficacy of Zhengjia Huoxue I prescription in the treatment of uterine leiomyoma of kidney deficiency and blood stasis and explore its mechanism.Enrich the clinical application of the theory of "Yang Hua qi,Yin Cheng Xing" and provide new opinions and ideas for clinical treatment of uterine leiomyoma.Methods:From June 2019 to June 2020,72 patients with uterine leiomyoma of kidney deficiency and blood stasis were randomly divided into treatment group(n=36)and control group(n=36).The treatment group was given Zhengjia Huoxue I prescription,once a day,taken separately in the morning and evening.The control group was given rhubarb caterpillar capsule twice a day,4 capsules each time.Both of two groups were given 14 days after menstruation,and the menstrual cycle was continuously taken for 6 months.The changes of uterine volume、 leiomyoma、IGF-1、TGF-β1 、 TGF-β3 and TCM syndrome scores were observed three times including before treatment 、 3 months after treatment and 6 months after treatment.Use SPSS23.0 statistical to analyse.SPSS23.0 was used to observe the efficacy and safety of Zhengjia Huoxue I prescription in the treatment of uterine fibroids with kidney deficiency and blood stasis.Results: 1.Baseline data: There was no significant difference in age and course of disease between the two groups(P>0.05).2.Ultrasound examination: After 3 months of treatment,there was no significant difference in uterine volume and leiomyoma between the two groups(P > 0.05).After 6 months of treatment,the uterine volume and leiomyoma of the two groups were smaller than those before treatment(P<0.05),and the treatment group was better than the control group(P < 0.05).3.Serological tests: After 3 months of treatment,the levels of IGF-1 and TGF-β1 in both groups were lower than those before treatment(P<0.05),and there was no significant difference between the two groups(P > 0.05).TGF-β3 levels in the two groups were not significantly different from those before treatment(P > 0.05),and there was no significant difference between the two groups(P > 0.05).4.Serological tests: After 6months of treatment,the levels of IGF-1 and TGF-β1 in both groups were lower than those before treatment(P< 0.05),and those in the treatment group were better than those in the control group(P < 0.05).TGF-β3 levels in both groups were lower than those before treatment(P<0.05),and there was no significant difference between the two groups(P > 0.05).5.TCM syndrome score: After 3 months of treatment,TCM syndrome score in both groups decreased compared with that before treatment(P<0.05).The effective rate of TCM syndrome in the treatment group and the control group were 94.29% and 42.86%.The treatment group was better than the control group(P<0.05).After 6 months of treatment,the effective rates of TCM syndromes in the treatment group and the control group were 94.29% and 65.71%.The treatment group was better than the control group(P < 0.05).6.Evaluation of the efficacy of uterine fibroids: After 6 months of treatment,the clinical efficacy of uterine fibroids in the treatment group and the control group were 91.43% and 80.00%.The treatment group was better than the control group(P<0.05).Conclusion: 1.The uterine volume and fibroid body of patients with kidney deficiency and blood stasis were significantly reduced by Zheng Jia Huo Xue I prescription.2.Zheng Jia Huo Xue I prescription is possible to reduce uterine fibroids by reducing IGF-1,TGF-β1 and TGF-β3 levels in human body.3.Zheng Jia Huo Xue I prescription can significantly improve the clinical symptoms and signs of kidney deficiency and blood stasis.4.Based on the theory of "Yang Hua Qi,Yin Cheng Xing",Zheng Jia Huo Xue I has been formulated with definite clinical efficacy and no obvious adverse reactions.It is safe and reliable,providing new insights and ideas for the clinical treatment of uterine fibroids. |
PDF Full Text Request